Immunology

Cancer tumour
#Cancer therapeutics #Clinical trials #Immunology #Society of Immunotherapy for Cancer (SITC) #Storm Therapeutics

New clinical data on first-in-class METTL3 inhibitor 

Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024.    The Phase I clinical study… Read More

#News

#Collaboration #Immunology #License agreement #Monte Rosa Therapeutics #Novartis

Novartis and Monte Rosa partner on molecular glue degraders

Monte Rosa Therapeutics and Novartis have agreed a global license agreement to advance VAV1 molecular glue degrader-based medicines (MGDs). The deal includes MRT-6160, which is currently in an ongoing Phase I study for immune-mediated conditions. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture… Read More

#Business & Investment #News

Cancer research in lab
#Antigen #Immunology #Oncology #Prostate cancer #University of California San Francisco

Study reveals insights into antigen reactivity in prostate cancer

Researchers from the University of California, San Francisco (UCSF) shared new data on foundational prostate cancer antigen research at the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago. Prostate cancer’s low mutation burden has resulted in very few druggable neoantigens –… Read More

#Cancer Research #News

#Cancer drug targets #Cancer research #eFFECTOR #Immunology #Selective Translation Regulator Inhibitor (STRI)

New podcast episode: Depriving cancer of what it needs

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Steve Worland,… Read More

#News

#Antibodies #Cancer #Cancer research #Diagnostics #Drug discovery #Fibroblasts #Flow Cytometry #Immunology #Oncology #Tumour biology

Podcast: Flow cytometry for drug discovery research

This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging… Read More

#News

DNA research molecule
#CAR-T #DNA #Epigenomics #Genetic editing #Genomics #Immunology #Oncology #Tune Therapeutic

Moving the needle of CAR-T beyond oncology 

CAR-T Therapies have revolutionised the field of personalised medicine, especially in oncology. DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology making… Read More

#Cancer Research #Exclusive Content

Doctor prepares vaccine
#Funding #Immunology #Immunology / Virology & Vaccines #Pandemic prevention #University of Oxford

University of Oxford receives £7.8 million to fight pandemic threats

The Oxford Vaccine Group (OVG), which led the development of the Oxford vaccine for Covid-19, has been awarded a total of £7.8 ($9.8) million by UK Aid for research into the prevention of five diseases with epidemic or pandemic potential. The awards will fund research into… Read More

#News

Therapeutic antibodies
#Antibodies #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies

Finding the North Star of therapeutic antibodies

Listen to this article on the DDW Podcast: Katie Abouzahr is the Vice President, Autoantibody Portfolio and Maternal Fetal Disease Area Leader at the Janssen Pharmaceutical Companies of Johnson & Johnson. She speaks with Megan Thomas about the future for Janssen’s investigational medicine nipocalimab and antibody therapeutics at large. A day in… Read More

#Exclusive Content

Cancer cells
#biological engineering #Bolt Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Immunology

New podcast: In conversation with Shelley Ackerman, Bolt Biotherapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Shelley… Read More

#News

Long Covid
#Covid-19 #Immunology #Long Covid #Psychiatry #SARS-CoV-2

New post-Covid study links infection and retrovirus 

A Translational Psychiatry publication indicates that SARS-CoV-2 infection, even when unnoticed or asymptomatic, can have an influence on the activation of the Human Endogenous Retrovirus W (W-ENV) protein in psychotic patients, in a context of innate immune inflammation.   GeNeuro, a biopharmaceutical company developing treatments… Read More

#Covid-19 #News

Innovation
#Advanced Therapies #Animal models #Autoimmune disease #Cell and gene therapy #Data #Genetics / genomics #Immunology #Pharma

New podcast on animal genomics, immunology and CGTs

This is the latest episode of the free DDW narrated podcast, “What’s at the forefront of innovation?” It covers three articles written for the for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Can animal genomics help find… Read More

#News

#Biopharmaceuticals #Collaboration #Contract Research Organisations (CROs) #Cryo-EM #Drug research #Immunology #Oncology

What’s next for this integrated drug discovery collaboration? 

Galapagos and NovAliX have entered a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organisation. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and… Read More

#News

Macrophage
#Cancer research #Immunology #Macomics #Mass spectrometry / NMR #Oncology #Transcriptomics #Tumour biology #Tumour microenvironment (TME)

Scottish company will target macrophages to treat cancer

Newly published discoveries have revealed possibilities for the treatment of cancer by targeting tumour-associated macrophages (TAMs) in the tumour microenvironment (TME).  The founding scientists behind Edinburgh-based Macomics, Dr Luca Cassetta and Professor Jeff Pollard, detail the seminal discoveries in macrophage biology over the past 50 years in… Read More

#Cancer Research #News

#Biologics #Cancer research #Cancer treatment #Immunology #Oncology

Biologics and living drugs: entering a new era of cancer treatment

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More

#Cancer Research #Exclusive Content

Flow cytometry
#Cancer #Cancer research #Fibroblasts #Flow Cytometry #Immunology #Oncology #Tumour biology

Flow cytometry technologies and cancer associated fibroblasts

Listen to this article on the DDW podcast: Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. Inside any solid tumour there is high heterogeneity, and the types of tumour cells,… Read More

#Exclusive Content

#AI #Drug Discovery 2022 #Genomics #Immunology #Nanomedicine / nanotechnology #Personalised medicine

Sharing knowledge to fuel the revolution

Here, we speak with two of the keynote speakers at this year’s Drug Discovery 2022, Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine at Imperial College London, and Rab Prinjha, VP Head of Immunology Research Unit at GlaxoSmithKline, about the insights they will be sharing and what they see as the… Read More

#Exclusive Content